Peptide COA Data Integrity: ALCOA+, Audit Trails and the Records Behind a Purity Number

Peptide COA data integrity refers to the completeness, traceability and verifiability of the underlying analytical records that produce a certificate of analysis, not to the summary number printed on the document. A purity figure is a conclusion. The chromatograms, mass spectra, instrument audit trails, integration parameters and reference standard records behind that figure are the evidence, and without them the conclusion cannot be independently checked.

This distinction matters more in research peptides than in almost any other supply category. A certificate of analysis is a one page PDF that can be produced by a laboratory, edited by a distributor, or fabricated outright, and the buyer usually has no way to tell which happened. Regulators solved this problem for pharmaceutical manufacturing decades ago by requiring that the record, not the report, be the controlled object. Applying the same logic to research peptide procurement is straightforward, and it changes what a researcher should be asking a supplier for.

What data integrity means in an analytical context

The governing framework is ALCOA, an acronym that originated in United States Food and Drug Administration investigator training and now appears in guidance worldwide. Data must be attributable to the person or instrument that generated it, legible and permanent, contemporaneous with the activity, original or a certified true copy, and accurate. The expanded ALCOA+ formulation adds four further attributes: complete, consistent, enduring and available. Nine attributes in total, and a certificate of analysis distributed as a flat PDF with no linked source records satisfies almost none of them.

Several regulatory documents codify this. The FDA published its final guidance, Data Integrity and Compliance With Drug CGMP: Questions and Answers, in December 2018. The United Kingdom Medicines and Healthcare products Regulatory Agency issued GXP Data Integrity Guidance and Definitions, revision 1, in March 2018. The Pharmaceutical Inspection Co-operation Scheme guidance PI 041-1, Good Practices for Data Management and Integrity in Regulated GMP and GDP Environments, took effect on 1 July 2021. The World Health Organization addressed the same ground in Technical Report Series 996, Annex 5, published in 2016.

The specific United States regulation is worth quoting in substance because it is unusually direct. Under 21 CFR 211.194(a), laboratory records must include complete data derived from all tests conducted, including graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific component, container and lot tested. The regulation does not permit a laboratory to retain only its conclusions. Separately, 21 CFR Part 11 governs electronic records and electronic signatures, and it is the reason modern chromatography data systems maintain immutable audit trails.

Why identity errors survive a purity number

The strongest argument for record level verification is not theoretical. It comes from analytical surveys of peptide products circulating outside regulated supply chains, and the findings are specific enough to be uncomfortable.

Glycine extended secretagogues

Krug, Thomas, Malerod-Fjeld, Dehnes, Laussmann, Feldmann, Sickmann and Thevis reported in Growth Hormone and IGF Research in 2018 (volume 41, pages 1 to 6) on the characterisation of growth promoting products obtained from unregulated channels. Among the findings was a modified growth hormone consisting of 192 amino acids carrying an additional alanine at the N terminus, giving a monoisotopic mass of 22,195 Da. The same work identified three growth hormone releasing peptide analogues that had each been extended by a single N terminal glycine residue: Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin.

Consider what that means analytically. A glycine residue adds roughly 57 Da to a peptide backbone. On a reversed phase gradient, a glycine extended analogue frequently elutes as a single symmetric peak with near baseline resolution from nothing in particular, because there is nothing else in the vial to resolve it from. Integrated by area percent at 214 nm, that peak can report above 99 percent. The material is chemically homogeneous. It is simply not the compound named on the label. Purity and identity are orthogonal questions, and a certificate that answers only the first has answered the easier one.

Composition surveys of unregulated product

The broader picture comes from a survey published by Krug, Thomas, Walpurgis, Piper, Sigmund, Schanzer, Laussmann and Thevis in the European Journal of Clinical Pharmacology in 2014 (volume 70, issue 11, pages 1303 to 1311). Working with the German Bureau of Customs Investigation under the European Monitoring Center for Emerging Doping Agents, the Cologne Anti-Doping Laboratory analysed 337 products seized between 2010 and 2013 using liquid chromatography high resolution mass spectrometry, gas chromatography high resolution mass spectrometry, and polyacrylamide gel electrophoresis followed by bottom up identification by nano liquid chromatography tandem mass spectrometry.

Across those 337 products the laboratory identified 67 distinct active ingredients, of which 49 were classified as doping agents by the World Anti-Doping Agency. Steroidal substances accounted for 83.7 percent of findings, peptide hormones and growth factors for 12.8 percent, hormones and metabolic modulators for 3.2 percent, and diuretic agents for 0.3 percent. Notable individual identifications included the selective androgen receptor modulator LGD-4033, thymosin beta 4, and a fusion protein of unknown biological activity. That last item is the one worth sitting with. A protein construct entered circulation that no one could assign a function to, which means no label description of it could have been accurate.

Key Research Findings

• Krug et al., Growth Hormone and IGF Research, 2018, 41:1-6, characterised a 192 residue growth hormone variant with an additional N terminal alanine and a monoisotopic mass of 22,195 Da.
• The same study identified three N terminally glycine extended secretagogue analogues: Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin. A glycine extension shifts molecular mass by approximately 57 Da and is invisible to ultraviolet area percent purity alone.
• Krug et al., European Journal of Clinical Pharmacology, 2014, 70(11):1303-1311, analysed 337 seized products and identified 67 active ingredients, 49 of them WADA classified doping agents.
• Composition breakdown across those 337 products: 83.7 percent steroidal, 12.8 percent peptide hormones and growth factors, 3.2 percent hormones and metabolic modulators, 0.3 percent diuretics.
• Outlier findings in the 2014 survey included LGD-4033, thymosin beta 4, and a fusion protein of unknown biological activity.
• Regulatory basis for record level verification: FDA final guidance on data integrity and CGMP (December 2018), MHRA GXP Data Integrity Guidance revision 1 (March 2018), PIC/S PI 041-1 (effective 1 July 2021), WHO TRS 996 Annex 5 (2016), and 21 CFR 211.194(a).

Audit trails and the chromatography data system

Modern chromatography data systems record far more than a peak table. Every acquisition carries a timestamp, an operator identity, the instrument method, the column serial number, the reference standard lot, and a complete history of any change made to integration parameters after acquisition. That history is the audit trail, and it is the single most informative artefact in an analytical package because it distinguishes a result that was measured from a result that was adjusted until it was acceptable.

Manual reintegration is the classic failure mode. An analyst who widens a baseline window, shifts a valley to valley drop line, or excludes a shoulder can move a reported purity figure by a full percentage point without altering a single molecule in the vial. Nothing about that is inherently improper. Reintegration is sometimes analytically correct. What makes it defensible is that the audit trail records who did it, when, and why, and that the original integration remains retrievable. A PDF certificate strips all of this away and presents only the final number.

The related failure is trial injection, sometimes called testing into compliance. A sample is injected repeatedly and only a passing run is reported. In a compliant system the audit trail shows every injection, including the ones that failed, and any result outside specification triggers a formal investigation rather than a quiet reinjection. Research peptide buyers rarely see this layer, which is precisely why the number on its own carries less information than it appears to.

What a certificate of analysis can and cannot establish

A well constructed certificate establishes several things: the compound name and sequence, the batch identifier, the analytical methods applied, the acceptance criteria, the results obtained, the date of analysis, and the identity of the laboratory that performed the work. That is genuinely useful information and it is more than most suppliers in this category provide.

What it cannot establish on its own is whether the analysis was performed on the batch you received. This is the weakest link in the entire chain and it is a logistics problem rather than an analytical one. If the certificate carries a batch number and the vial carries no batch number, or carries a different one, the document is decorative. Batch level traceability from the analysed sample through to the labelled container is what converts a certificate from marketing collateral into evidence, and it is the reason batch specific documentation matters more than the headline purity figure. Our approach to independent third party certificates of analysis is built around that principle.

A certificate also cannot establish that the method was fit for the analyte. A purity assay that has not been validated for specificity may fail to separate a critical impurity from the main peak entirely, in which case the reported figure is precise and wrong. The governing framework for this is ICH Q2, and the relationship between method validation and reportable results is covered in our discussion of analytical method validation for research peptides.

Orthogonal confirmation and the reference standard chain

The practical answer to identity risk is orthogonal confirmation. Reversed phase chromatography separates by hydrophobicity. Mass spectrometry measures mass to charge ratio. Amino acid analysis measures composition. Each is blind to something the others catch. A glycine extended analogue that co-elutes cleanly is caught immediately by accurate mass because 57 Da is an enormous shift by mass spectrometric standards, but it can pass a chromatographic purity assay untouched.

Underneath all of it sits the reference standard. Every quantitative result is expressed relative to a characterised material, and the traceability of that material determines whether numbers from two laboratories can be compared at all. This is not an abstract concern. Interlaboratory variation in reported peptide purity frequently traces back to differences in standard characterisation rather than to genuine differences in the sample, a subject we examine in detail in our review of reference standards and interlaboratory comparability.

When a result does fall outside specification, the response is itself a data integrity question. A documented investigation that determines root cause before any retesting is the compliant path. Discarding the result and reporting a second run is not, and the audit trail is what distinguishes the two. The mechanics of that process are set out in our article on out of specification results and retesting.

Practical questions a researcher can ask

Three questions separate suppliers who hold records from suppliers who hold PDFs. First, does the certificate carry a batch identifier that appears on the physical container. Second, does the certificate name the laboratory that performed the analysis rather than only the distributor. Third, are the underlying chromatograms and mass spectra available on request rather than only the summary table. A supplier who can answer all three is operating a record system. A supplier who can answer none is circulating a document.

None of this requires a researcher to become an analytical chemist. It requires treating the certificate as a pointer to evidence rather than as the evidence itself, which is the same posture every regulated laboratory already takes. The full catalogue of compounds and accompanying documentation is available on our research peptide catalogue.

Frequently asked questions

What is ALCOA+ in peptide analysis?

ALCOA+ is a set of nine attributes that analytical data must satisfy to be considered reliable: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available. It originated in FDA investigator practice and now appears in MHRA, PIC/S and WHO guidance. Applied to a peptide certificate of analysis, it means the certificate must be traceable back to timestamped, operator attributed raw data that has not been silently altered.

Can a peptide be 99 percent pure and still be the wrong compound?

Yes. Purity and identity are separate measurements. A chromatographic purity assay reports how much of the injected material eluted as a single peak. It does not confirm what that peak is. The glycine extended secretagogue analogues described by Krug and colleagues in 2018 illustrate the point: chemically homogeneous material that is not the labelled compound. Identity requires an orthogonal method, most commonly mass spectrometry.

Why do audit trails matter if the final result is correct?

Because without the audit trail there is no way to establish that the final result is correct. The audit trail is what shows that a reported figure came from a single acquisition rather than from repeated attempts, and that any post acquisition change to integration was recorded and justified. It converts an assertion into a verifiable claim.

What should a batch specific certificate of analysis contain?

At minimum: compound name and sequence, batch identifier matching the physical container, analytical methods used, acceptance criteria, results with units, date of analysis, and the identity and signature of the performing laboratory. Chromatograms and mass spectra attached or available on request substantially strengthen the document.

Summary

Peptide COA data integrity is a records question before it is a chemistry question. The analytical literature on unregulated peptide products shows that identity errors are real, specific and undetectable by purity measurement alone, with glycine extended secretagogue analogues and an unidentifiable fusion protein among the documented findings. The regulatory answer developed for pharmaceutical manufacturing applies without modification: keep the raw data, keep the audit trail, tie every certificate to a batch, and treat the summary figure as a pointer rather than a proof.

The orthogonal confirmation described above depends on methods documented elsewhere in this collection. Identity verification by mass spectrometry answers a question chromatographic purity cannot, and the practical reading of the resulting document is covered in how to read a certificate of analysis. The limits of extending a batch figure to a single container are discussed in peptide vial content uniformity.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.